Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT02284425
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 708
- Registration Number
- NCT02277769
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 671
- Registration Number
- NCT02277743
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02265952
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 740
- Registration Number
- NCT02260986
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 194
- Registration Number
- NCT02210780
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT02127801
Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT02121080
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT02107872
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT02097524
© Copyright 2024. All Rights Reserved by MedPath